List view / Grid view
20 March 2013 | By Abbott
"We appreciate the FDA's dedication of time and resources..."
19 March 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company announced today the initiation of a Phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albuminuria, and urinary albumin-to-creatinine (UACR) ratio 30-3000 mg/g creatinine, in addition to current standard therapy for diabetic nephropathy.…
19 March 2013 | By AstraZeneca
PATHOS a real-world retrospective study...
19 March 2013 | By Biogen Idec
Patent offers protection until 2028 and strengthens growing product patent portfolio...
19 March 2013 | By Amgen
These are the first Phase 3 results of this novel approach to cancer therapy...
19 March 2013 | By InvivoSciences Inc.
Torrey Pines Institute for Molecular Studies and InvivoSciences collaborate to accelerate drug discovery in cardiac disease...
18 March 2013 | By AstraZeneca
Centres positioned to take better advantage of bioscience clusters...
18 March 2013 | By Novartis
Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole...
18 March 2013 | By Roche
The EMA has expanded the approval of Pegasys...
18 March 2013 | By Novo Nordisk
Novo Nordisk announced the headline results from a 56-week, double-blind phase 3a clinical trial...
16 March 2013 | By Daiichi Sankyo
Results of the PRASFIT-ACS study...
15 March 2013 | By Novartis
First filing for LDK378 anticipated in early 2014...
Lonza Walkersville, Inc. and Hyglos GmbH, a German biotech company, announced today that they have reached a mutually beneficial global settlement which includes a license agreement for Hyglos under certain Lonza patents in the area of endotoxin detection.
14 March 2013 | By Pegasus
The EC has approved expanded options for pre-treatment prior to use of QUTENZA...
13 March 2013 | By Novartis
New data will be presented...
